Video

Dr. Furman on Differences Between BTK Inhibitors in B-Cell Malignancies

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Richard R. Furman, MD, professor of medicine; Morton Coleman, MD Distinguished Professor of Medicine; director of the CLL Research Center at Weill Cornell Medical College, Weill Cornell Medicine, and attending physician at New York-Presbyterian Hospital, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

To date, ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are the 3 BTK inhibitors that have received regulatory approval in the United States, Furman says. Ibrutinib is a first-generation BTK inhibitor while zanubrutinib and acalabrutinib are second-generation BTK inhibitors, Furman explains.

Since all 3 agents have the same bind covalently to the same residue and they operate using the same mechanism of action with regard to their efficacy, the main differences among them are in terms of their specificity and drug–drug interaction, Furman adds.

Notably, when comparing acalabrutinib and zanubrutinib with ibrutinib, fewer off-target effects are observed. The safety profiles of these drugs also differ, Furman adds. Additionally, because of the differences in how these BTK inhibitors are metabolized, there is a significant contrast in the way they interact with other drugs, Furman concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity